Influence of concentration and injection volume on the bioavailability of subcutaneous growth hormone: comparison of administration by ordinary syringe and by injection pen.

What Was Tested

The paper reports a study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over), published as a randomized controlled trial.

Blood samples were drawn over a 14 hr period and assayed for serum concentrations of GH and IGF-I.

The mean value (+/- S.D.) of the relative absorption fraction (Fpen/sy) was 1.09 +/- 0.39.

Who Took Part

The age groups tagged for this paper are adults and middle-aged adults, both men and women.

In order to study whether the bioavailability of subcutaneously injected growth hormone (GH) is dependent on the concentration/volume injected, the relative GH bioavailability was evaluated in 14 GH-deficient patients.

How the Study Was Run

The design is described as randomized and crossover.

Because people in this Exogenous HGH, sermorelin & older GHRPs (why they're passed over) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Each person switched between Exogenous HGH, sermorelin & older GHRPs (why they're passed over) and the comparison at some point, usually with a gap in between.

What Was Measured

PubMed files the paper under topics including Biological Availability, Growth Hormone and Injections, Jet.

What This Means in Plain Language

The paper is a randomized and crossover study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over).

The publication is from 1991 (Pharmacology & toxicology), a journal based in Denmark.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.